These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12691205)

  • 1. Preventing problems in Ecstasy users: reduce use to reduce harm.
    Baggott MJ
    J Psychoactive Drugs; 2002; 34(2):145-62. PubMed ID: 12691205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The health effects of ecstasy: a literature review.
    Gowing LR; Henry-Edwards SM; Irvine RJ; Ali RL
    Drug Alcohol Rev; 2002 Mar; 21(1):53-63. PubMed ID: 12189005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users.
    Soar K; Parrott A; Turner J
    J Psychopharmacol; 2009 Sep; 23(7):745-58. PubMed ID: 18635698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDMA misrepresentation: an unresolved problem for Ecstasy users.
    Hayner GN
    J Psychoactive Drugs; 2002; 34(2):195-8. PubMed ID: 12691209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E; Daumann J
    Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDMA/Ecstasy use among young people in Ohio: perceived risk and barriers to intervention.
    Carlson RG; Falck RS; McCaughan JA; Siegal HA
    J Psychoactive Drugs; 2004 Jun; 36(2):181-9. PubMed ID: 15369199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.
    Parrott AC; Buchanan T; Scholey AB; Heffernan T; Ling J; Rodgers J
    Hum Psychopharmacol; 2002 Aug; 17(6):309-12. PubMed ID: 12404677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of use and harm reduction practices of ecstasy users in Australia.
    Allott K; Redman J
    Drug Alcohol Depend; 2006 Apr; 82(2):168-76. PubMed ID: 16226850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
    Parrott AC
    J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of acute psychotic episode after a single dose of ecstasy].
    Vaiva G; Bailly D; Boss V; Thomas P; Lestavel P; Goudemand M
    Encephale; 2001; 27(2):198-202. PubMed ID: 11407274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk.
    Silins E; Copeland J; Dillon P
    Aust N Z J Psychiatry; 2007 Aug; 41(8):649-55. PubMed ID: 17620161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy.
    Parrott AC
    J Psychopharmacol; 2005 Jan; 19(1):71-83. PubMed ID: 15671132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use.
    Gouzoulis-Mayfrank E; Fischermann T; Rezk M; Thimm B; Hensen G; Daumann J
    Drug Alcohol Depend; 2005 Jun; 78(3):317-23. PubMed ID: 15893163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dancing hot on Ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems reported by recreational MDMA users.
    Parrott AC; Rodgers J; Buchanan T; Ling J; Heffernan T; Scholey AB
    Hum Psychopharmacol; 2006 Jul; 21(5):285-98. PubMed ID: 16856221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences between Ecstasy-using and nonusing methamphetamine users.
    Brecht ML; von Mayrhauser C
    J Psychoactive Drugs; 2002; 34(2):215-23. PubMed ID: 12691212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users.
    Fox HC; McLean A; Turner JJ; Parrott AC; Rogers R; Sahakian BJ
    Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mental disorders in current and former heavy ecstasy (MDMA) users.
    Thomasius R; Petersen KU; Zapletalova P; Wartberg L; Zeichner D; Schmoldt A
    Addiction; 2005 Sep; 100(9):1310-9. PubMed ID: 16128720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contextualising psychological distress among regular ecstasy users: the importance of sociodemographic factors and patterns of drug use.
    George J; Kinner SA; Bruno R; Degenhardt L; Dunn M
    Drug Alcohol Rev; 2010 May; 29(3):243-9. PubMed ID: 20565515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.
    Soar K; Turner JJ; Parrott AC
    J Psychopharmacol; 2006 May; 20(3):417-24. PubMed ID: 16574716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users.
    Gouzoulis-Mayfrank E; Thimm B; Rezk M; Hensen G; Daumann J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):819-27. PubMed ID: 12921915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.